Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
Postdoc Maria Taskinen wins ICR Science and Medical Image Competition 2025
Seven images were shortlisted for this year’s annual Science and Medical Image competition, showcasing the eye-catching science being carried out at the ICR. Three winners were selected by a judging panel and the fourth was chosen by the public based on votes on social media.
New research reveals how combining viruses with targeted drugs can boost cancer-killing immune responses
Two studies have uncovered how combining a cancer-killing reovirus with targeted cancer drugs can dramatically boost immune responses and tumour destruction – offering a promising route to more effective, personalised cancer therapies.